stockrowCogent Biosciences, Inc.
COGT Healthcare Biotechnology
- EPS
- +1.89%
- Free cash flow
- −42.0%
Quarter to June 2026, against a year earlier
Follow COGT
Alert me
Cogent Biosciences, Inc. (COGT) Return on equity
Cogent Biosciences, Inc.'s return on equity over the twelve months to 30 June 2026 was −146.6%, down 51.6 percentage points from fiscal 2025 (−95.0%). Over the past ten years it has ranged from −606.7% (fiscal 2018) to 69.5% (fiscal 2017); the current reading is higher than 45% of that period. That is below the Biotechnology industry median of −52.0% and below the Healthcare sector median of −26.0%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −95.0% | 54.01 |
| FY2024 | −149.0% | (49.73) |
| FY2023 | −99.3% | (11.25) |
| FY2022 | −88.0% | (30.78) |
| FY2021 | −57.2% | 173.19 |
| FY2020 | −230.4% | (161.21) |
| FY2019 | −69.2% | 537.53 |
| FY2018 | −606.7% | (676.24) |
| FY2017 | 69.5% | 20.04 |
| FY2016 | 49.5% | 49.46 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| MANE Veradermics Incorporated compare | 0.00% |
| DNTH Dianthus Therapeutics, Inc. compare | −22.6% |
| CRSP CRISPR Therapeutics AG compare | −25.6% |
| ERAS Erasca, Inc. compare | −78.3% |
| COGT Cogent Biosciences, Inc. | −146.6% |
| SRRK Scholar Rock Holding Corporation compare | −167.8% |
| TVTX Travere Therapeutics, Inc. compare | −252.8% |
| KOD Kodiak Sciences Inc. compare | −368.4% |
| Biotechnology industry median | −52.0% |
| Healthcare sector median | −26.0% |
| Market median | 1.01% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on COGT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement